Why BioNTech, Moderna, and Novavax Stocks Soared This Week_老虎社区_美港股上老虎

Why BioNTech, Moderna, and Novavax Stocks Soared This Week

Motley Fool2021-07-23

What happened Shares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week. The common denominator driving all ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

willnlol
·2021-07-26
End end
回复
1
举报
KLok
·2021-07-24
Better luck next week.....
回复
点赞
举报
Jazzc85
·2021-07-23
They soar as the cases soar..
回复
1
举报
Atwosome
·2021-07-23
Good sharing
回复
6
举报
收起
- Atwosome:
  ok
  2021-07-23
  回复
  举报
- Sunshine88:
  Like and comment
  2021-07-24
  回复
  举报
DonaldL
·2021-07-23
Ok
回复
1
举报
收起
- Atwosome:
  ok
  2021-07-23
  回复
  举报
2c077e4d
·2021-07-23
Like and comment
回复
5
举报
收起
- thuiminn:
  like and comment
  2021-07-23
  回复
  举报
- Chibichibi:
  Ok
  2021-07-23
  回复
  举报
- trashbin:
  Ok
  2021-07-23
  回复
  举报
RossT
·2021-07-23
Supported by hike in cases
回复
3
举报
收起
- GCL08:
  Unfortunatel….yes
  2021-07-23
  回复
  举报
JDO
·2021-07-23
Like please
回复
2
举报
收起
- S土豪熊貓G:
  Ok
  2021-07-23
  回复
  举报
- Jklya:
  Ok
  2021-07-23
  回复
  举报
JustinAQX
·2021-07-23
Nightmare please end
回复
5
举报
收起
- willnlol:
  endddd
  2021-07-27
  回复
  举报
- willnlol:
  end ene
  2021-07-26
  回复
  举报
- Mythology:
  🤪🤪
  2021-07-24
  回复
  举报
查看更多 2 条评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2153198394?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-23 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2153198394","market":"us","top_or_hot":-1,"title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","media":"Motley Fool","content":"<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","article_id":"2153198394","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","pubTimestamp":1627034820,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Concerns about the delta variant are rising.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","MRNA":"Moderna, Inc."},"translate_title":"为什么生物技术公司、莫德纳公司和诺瓦瓦克斯医药公司的股票本周飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNCF":0.9,"BNTX":0.9,"MRNA":0.9,"NVAX":0.9,"PFE":0.9},"content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","kind":"highlight","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":800882520,"gmtCreate":1627290990160,"gmtModify":1631889058117,"author":{"id":"3578871663749183","authorId":"3578871663749183","name":"willnlol","avatar":"https://static.tigerbbs.com/208844269ff22e7e65d50d6a8f09c6d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578871663749183","authorIdStr":"3578871663749183"},"htmlText":"End end","listText":"End end","text":"End end","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800882520","repostId":2153198394,"repostType":2,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":174483389,"gmtCreate":1627126156941,"gmtModify":1631893770706,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582450584533032","authorIdStr":"3582450584533032"},"htmlText":"Better luck next week.....","listText":"Better luck next week.....","text":"Better luck next week.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/174483389","repostId":2153198394,"repostType":2,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":175579421,"gmtCreate":1627044335863,"gmtModify":1633768521373,"author":{"id":"3581583688503326","authorId":"3581583688503326","name":"Jazzc85","avatar":"https://static.tigerbbs.com/56b42e602a7cb8788c5ed131adee25cc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581583688503326","authorIdStr":"3581583688503326"},"htmlText":"They soar as the cases soar..","listText":"They soar as the cases soar..","text":"They soar as the cases soar..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/175579421","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":175505183,"gmtCreate":1627039363142,"gmtModify":1633768567752,"author":{"id":"3571305152732730","authorId":"3571305152732730","name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3571305152732730","authorIdStr":"3571305152732730"},"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/175505183","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5305579,"gmtCreate":1627039371228,"gmtModify":1635223037695,"authorId":3571305152732730,"author":{"id":3571305152732730,"idStr":"3571305152732730","authorId":3571305152732730,"name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175505183,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":5312632,"gmtCreate":1627086399521,"gmtModify":1635222682764,"authorId":3586140387931872,"author":{"id":3586140387931872,"idStr":"3586140387931872","authorId":3586140387931872,"name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175505183,"type":1,"supId":5305579,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":175276984,"gmtCreate":1627038574848,"gmtModify":1633768573589,"author":{"id":"3566684989982146","authorId":"3566684989982146","name":"DonaldL","avatar":"https://static.tigerbbs.com/5d913d97919adf9f7d3c525aa1cc3a9c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3566684989982146","authorIdStr":"3566684989982146"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175276984","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5305580,"gmtCreate":1627039380173,"gmtModify":1635223037586,"authorId":3571305152732730,"author":{"id":3571305152732730,"idStr":"3571305152732730","authorId":3571305152732730,"name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175276984,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":175227861,"gmtCreate":1627036570153,"gmtModify":1631890096492,"author":{"id":"3581768035538210","authorId":"3581768035538210","name":"2c077e4d","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581768035538210","authorIdStr":"3581768035538210"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/175227861","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5306362,"gmtCreate":1627044165000,"gmtModify":1631890096517,"authorId":3582403330807441,"author":{"id":3582403330807441,"idStr":"3582403330807441","authorId":3582403330807441,"name":"thuiminn","avatar":"https://static.tigerbbs.com/ab77e304f9cf03ebe236699fa09e54b7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":5305239,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"},{"id":5305239,"gmtCreate":1627036856008,"gmtModify":1631890096506,"authorId":3582020670131796,"author":{"id":3582020670131796,"idStr":"3582020670131796","authorId":3582020670131796,"name":"Chibichibi","avatar":"https://static.tigerbbs.com/671a41a5ed2aa68a8f1cfd3e8d82402a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5305210,"gmtCreate":1627036719192,"gmtModify":1631890096496,"authorId":3581740009720756,"author":{"id":3581740009720756,"idStr":"3581740009720756","authorId":3581740009720756,"name":"trashbin","avatar":"https://static.tigerbbs.com/42bc5ae713c40f98d81014f3b0eb7def","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":175222282,"gmtCreate":1627036405846,"gmtModify":1633768588814,"author":{"id":"3571876457050464","authorId":"3571876457050464","name":"RossT","avatar":"https://static.tigerbbs.com/c05489dba5744564e34adf12817967c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571876457050464","authorIdStr":"3571876457050464"},"htmlText":"Supported by hike in cases","listText":"Supported by hike in cases","text":"Supported by hike in cases","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175222282","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5305169,"gmtCreate":1627036453116,"gmtModify":1635223055282,"authorId":3579045920422452,"author":{"id":3579045920422452,"idStr":"3579045920422452","authorId":3579045920422452,"name":"GCL08","avatar":"https://static.tigerbbs.com/3433a6063e0b2ab82ed571a0790eb790","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175222282,"type":1,"supId":0,"prevId":0,"content":"Unfortunatel….yes","text":"Unfortunatel….yes","html":"Unfortunatel….yes"}],"langContent":"EN"},{"id":175267675,"gmtCreate":1627035666697,"gmtModify":1633768592152,"author":{"id":"3581892285296151","authorId":"3581892285296151","name":"JDO","avatar":"https://static.tigerbbs.com/0773772b25da29d845e6408e45e12846","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581892285296151","authorIdStr":"3581892285296151"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/175267675","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5305465,"gmtCreate":1627038596231,"gmtModify":1635223042874,"authorId":3578811676095048,"author":{"id":3578811676095048,"idStr":"3578811676095048","authorId":3578811676095048,"name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175267675,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5305619,"gmtCreate":1627039741578,"gmtModify":1635223035957,"authorId":3586775290774178,"author":{"id":3586775290774178,"idStr":"3586775290774178","authorId":3586775290774178,"name":"Jklya","avatar":"https://static.tigerbbs.com/2b4e775fb0c4b7c8e2f2396397c6c1d9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175267675,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":175268942,"gmtCreate":1627035253786,"gmtModify":1631891602968,"author":{"id":"3583210090992024","authorId":"3583210090992024","name":"JustinAQX","avatar":"https://static.tigerbbs.com/c36857e7f55d5c0aa300ac68988e55a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583210090992024","authorIdStr":"3583210090992024"},"htmlText":"Nightmare please end&nbsp;","listText":"Nightmare please end&nbsp;","text":"Nightmare please end","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/175268942","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","kind":"highlight","pubTimestamp":1627034820,"share":"https://www.laohu8.com/m/news/2153198394?lang=&edition=full","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5346595,"gmtCreate":1627388659197,"gmtModify":1631891603023,"authorId":3578871663749183,"author":{"id":3578871663749183,"idStr":"3578871663749183","authorId":3578871663749183,"name":"willnlol","avatar":"https://static.tigerbbs.com/208844269ff22e7e65d50d6a8f09c6d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175268942,"type":1,"supId":0,"prevId":0,"content":"endddd","text":"endddd","html":"endddd"},{"id":5332864,"gmtCreate":1627291034311,"gmtModify":1631891603011,"authorId":3578871663749183,"author":{"id":3578871663749183,"idStr":"3578871663749183","authorId":3578871663749183,"name":"willnlol","avatar":"https://static.tigerbbs.com/208844269ff22e7e65d50d6a8f09c6d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175268942,"type":1,"supId":0,"prevId":0,"content":"end ene","text":"end ene","html":"end ene"},{"id":5311635,"gmtCreate":1627081183841,"gmtModify":1631891602999,"authorId":3581631227222192,"author":{"id":3581631227222192,"idStr":"3581631227222192","authorId":3581631227222192,"name":"Mythology","avatar":"https://static.tigerbbs.com/190cafdd30075e07fb377edd392ed682","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175268942,"type":1,"supId":0,"prevId":0,"content":"🤪🤪","text":"🤪🤪","html":"🤪🤪"},{"id":5306255,"gmtCreate":1627043652897,"gmtModify":1631891602987,"authorId":3583407436165034,"author":{"id":3583407436165034,"idStr":"3583407436165034","authorId":3583407436165034,"name":"AppleAdam","avatar":"https://static.tigerbbs.com/65f4b1f6fab199d2a76abacd86f3b9fc","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175268942,"type":1,"supId":0,"prevId":0,"content":"XD","text":"XD","html":"XD"},{"id":5305457,"gmtCreate":1627038536150,"gmtModify":1631891602975,"authorId":4088467012186210,"author":{"id":4088467012186210,"idStr":"4088467012186210","authorId":4088467012186210,"name":"andy1216","avatar":"https://static.tigerbbs.com/653530be86acad69c77bb71bf41481e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175268942,"type":1,"supId":0,"prevId":0,"content":"Yeaaa","text":"Yeaaa","html":"Yeaaa"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":81,"commentSize":9,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}